Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04213807 · ClinicalTrials.gov registry record · Phase 2
A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation
A Phase 2 study, sponsored by Anthos Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT04213807: Completed Phase 2 study, sponsored by Anthos Therapeutics.
NCT04213807 is a Phase 2 study that has completed, run by Anthos Therapeutics. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04213807, a Phase 2 study, has completed, sponsored by Anthos Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in patients with atrial fibrillation (AF) or flutter at low risk of thromboembolic stroke or peripheral embolism.
Primary Outcome
Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough after the third dose on Day 91 at different dose levels of MAA868
Interventions
- OTHER Placebo
- BIOLOGICAL MAA868 Cohort 1
- BIOLOGICAL MAA868 Cohort 2
- BIOLOGICAL MAA868 Cohort 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2021-03-08 |
| Phase | Phase 2 |
What the finished NCT04213807 record still lists
NCT04213807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04213807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04213807 about?
NCT04213807 is a clinical study titled "A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation". This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in patients with atrial fibrillation (AF) or f...
What is the current status of trial NCT04213807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-12-11. Estimated completion is 2021-03-08.
What interventions are being tested in trial NCT04213807?
The interventions under investigation include: Placebo (OTHER), MAA868 Cohort 1 (BIOLOGICAL), MAA868 Cohort 2 (BIOLOGICAL), MAA868 Cohort 3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04213807?
This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04213807's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI